Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company is headquartered in San Francisco, California and currently employs 618 full-time employees. The firm’s research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. The company leverages its chemistry platform to discover and design new drug airbenders. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. The company is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.